CHM Stock Overview
A clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Chimeric Therapeutics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.024 |
52 Week High | AU$0.055 |
52 Week Low | AU$0.021 |
Beta | 1.68 |
1 Month Change | -22.58% |
3 Month Change | -7.69% |
1 Year Change | -35.14% |
3 Year Change | -92.26% |
5 Year Change | n/a |
Change since IPO | -91.72% |
Recent News & Updates
Recent updates
Shareholder Returns
CHM | AU Biotechs | AU Market | |
---|---|---|---|
7D | 4.3% | -0.5% | 1.5% |
1Y | -35.1% | -9.2% | 8.7% |
Return vs Industry: CHM underperformed the Australian Biotechs industry which returned -9.2% over the past year.
Return vs Market: CHM underperformed the Australian Market which returned 8.7% over the past year.
Price Volatility
CHM volatility | |
---|---|
CHM Average Weekly Movement | 12.4% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CHM's share price has been volatile over the past 3 months.
Volatility Over Time: CHM's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | n/a | n/a | www.chimerictherapeutics.com |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric.
Chimeric Therapeutics Limited Fundamentals Summary
CHM fundamental statistics | |
---|---|
Market cap | AU$20.55m |
Earnings (TTM) | -AU$11.73m |
Revenue (TTM) | AU$12.47m |
1.6x
P/S Ratio-1.8x
P/E RatioIs CHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CHM income statement (TTM) | |
---|---|
Revenue | AU$12.47m |
Cost of Revenue | AU$0 |
Gross Profit | AU$12.47m |
Other Expenses | AU$24.19m |
Earnings | -AU$11.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.014 |
Gross Margin | 100.00% |
Net Profit Margin | -94.06% |
Debt/Equity Ratio | 0% |
How did CHM perform over the long term?
See historical performance and comparison